How Do Peptides and Drugs Bind to the Peptide Transporters?  by Fowler, Philip W. et al.
Monday, March 7, 2011 247a1352-Pos Board B262
How Do Peptides and Drugs Bind to the Peptide Transporters?
Philip W. Fowler, Simon Newstead, Mark S.P. Sansom.
The peptide transporters (TC 2.A.17) are members of the Major Facilitator Su-
perfamily (MFS), the largest family of membrane protein transporters. PepT1
couples the transport of di- and tri-peptides across the lining of the gut to the
proton electro-chemical gradient and has also been shown to be responsible
for the uptake of several drugs, e.g. the beta-lactam antibiotics. How these
MFS transporters can bind and transport both peptides and a wide range of
drugs is not known. The occluded structure of PepTSo [1], a bacterial homo-
logue of PepT1, suggests that the peptide transporters can transport such
a wide range of substrates because the putative binding site not only contains
an electrical dipole but is also surrounded by large, amphipathic residues, no-
tably tyrosine, that can adapt to a wide range of sidechains and chemical
groups. We shall test these hypotheses using a combination of unbiased and
free energy simulations using molecular dynamics. Any transported substrate
must bind to the occluded state as well as the outward-facing state, otherwise
it may merely be an inhibitor. If successful, we hope to reveal not only insights
that will allow the bioavailability of drug candidates to be improved by target-
ing them for transport by PepT1 but also how these membrane proteins trans-
port molecules by changing their conformation.
1. Newstead S, Drew D, Cameron AD, Postis VLG, Xia X, Fowler PW, Carpen-
ter EP, Sansom MSP, McPheron MJ, Baldwin SA, Iwata S (2010). Crystal
structure of a prokaryotic homologue of the mammalian oligopeptide-proton
symporters, PepT1 and PepT2. Submitted.
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The Naþ-Ca2þ Exchanger is Required for Sinoatrial Node Pacemaker
Activity in Murine Myocardium
Sabine Groenke, Eric D. Larson, Rui Zhang, Haruko Nakano,
Maria C. Jordan, Kenneth P. Roos, Atsushi Nakano, Catherine Proenza,
Kenneth D. Philipson, Joshua I. Goldhaber.
To determine whether pacemaker activity in the murine sinoatrial node (SAN)
requires Naþ-Ca2þ exchange (NCX1) activity, we used cre/loxP technology to
generate mice with an atrial-specific knockout (KO) of NCX1 using a sarcolipin
promoter. NCX1 atrial KO mice live to adulthood. At 13 weeks, the heart to
body weight ratio is increased in KO (5.5 5 0.1 (n = 20)) versus wild type
(WT, 3.9 5 0.1 (n = 18); p &lt; 0.001). Atria are enlarged with thin walls
and show no evidence of NCX1 (including the SAN) on immunostaining. By
echocardiography, the left ventricle of the KO is dilated (end diastolic diameter
4.85 0.2 mm in KO ( n = 6); 3.65 0.2 mm in WT (n = 4); p = 0.002), and
there is a trend towards reduced fractional shortening. The heart rate is mark-
edly lower in KO (362.95 71.2 bpm, n = 6) compared to WT (524.95 56.9
bpm, n = 4, p = 0.005). ECG in KO reveals a junctional rhythm with no identifi-
able atrial activity (no P waves); this was confirmed using epicardial electrodes
in Langendorff-perfused hearts. KO atria loaded with the Ca2þ indicator Fluo3-
AM exhibit no spontaneous activity (in contrast to the spontaneous transients in
WT), but atrial Ca2þ transients can be elicited by external pacing. In patch
clamped SAN cells isolated from KO mice, there is no NCX activity in re-
sponse to caffeine-induced SR Ca2þ release. L-type Ca2þ current is decreased
in KO by ~50% but there is no difference in funny current (If) between WT and
KO. We conclude that NCX1 is required for pacemaker activity in the SAN.
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Dynamics of P-Glycoprotein: A Fluorescence and Disulfide Cross-Linking
Approach
Brandy Verhalen, Stefan Ernst, Michael Bo¨rsch, Stephan Wilkens.
P-glycoprotein (Pgp), a member of the ABC transporter family, couples ATP
hydrolysis to efflux of hydrophobic molecules including drugs used in chemo-
therapy. Here we used fluorescence resonance energy transfer (FRET) spectros-
copy to delineate the structural rearrangements the two NBDs are undergoing.
Cysteines introduced into equivalent regions in the N- and C-terminal NBDs of
cysteine-less mouse Pgp were labeled with fluorescent dyes for ensemble and
single molecule FRET (smFRET) spectroscopy with lipid-reconstituted Pgp.
In ensemble fluorescence experiments, adding substrate and/or nucleotide in-
creased the FRET efficiency for all mutants to varying degrees, suggesting
that the two NBDs approach one another upon substrate binding. Analysis of
smFRET data suggests that the NBDs of Pgp alternate between at least two ma-
jor conformations, a low and a high FRET state, during verapamil stimulated
ATP hydrolysis. Vanadate inhibition shifted the population toward the high
FRET state while the Pgp inhibitor cyclosporin resulted in a shift towards
the low FRET state. Furthermore, we have utilized direct disulfide cross-
linking to test whether complete dissociation of the NBDs is required for AT-
Pase stimulation by bulky drug molecules. Tethering the two NBDs together at
their C-terminal ends did not abolish drug stimulated ATP activity, indicatingthe motion the NBDs are undergoing is mainly on the level of the catalytic sites,
with the C-terminal ends of the NBDs acting as a hinge. Taken together, the
data provide an indication as to what the nature and magnitude of the structural
rearrangements are that Pgp is undergoing during the catalytic cycle.
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Determination of the Naþ/Glucose Cotransporter (SGLT1) Turnover Rate
using the Ion-Trap Technique
Jean-Philippe Longpre´, Jean-Yves Lapointe.
The Naþ/glucose cotransporter (SGLT1) is a membrane protein that couples the
transport of 2 Naþ ions and 1 glucose molecule using the ‘‘alternating access
mechanism’’. This mechanism involves the cotransporter oscillating between
two conformations characterized by intracellular versus extracellular accessibil-
ity to the binding sites. The turnover rate (TOR) is the number of complete cycles
that each cotransporter performs per second. It is a crucial parameter to establish
since it can be used to estimate the number of cotransporters present and it sets
a lower limit for the slowest rate constant involved in the cotransportmechanism
(conformational changes, binding and de-binding reactions). In this study, we
obtained an independent estimate of the TOR for human SGLT1 expressed in
Xenopus laevis oocytes using a new approach: the Ion-Trap technique (ITT,
Blanchard MG. et al. AJP 2008;295(5):C1464-72.) where an extracellular ion-
selective electrode of large diameter is used to detect the quantity of ions that
are rapidly taken up by the cotransporter (within 20 ms) when the binding sites
are suddenly exposed to the extracellular solution by application of a negative
membrane potential. Taking advantage of the fact that hSGLT1, in the absence
of Naþ, can cotransport glucose with protons, we used a pH electrode to deter-
mine a TOR of 8.00 5 1.3 s1 in the presence of 35 mM a-methyl-glucose
(aMG) at 150 mV (pH 5.5). This can be used to calculate a TOR of 13.35
2.4 s1, for the samegroup of oocytes, under nearVmax conditions i.e. in the pres-
ence of 90 mM Naþ and 5 mM aMG. Under these circumstances, the average
cotransport current was1.085 0.61mA (n=14) and this activitywas generated
by an average of 3.65 0.7 1011 cotransporter molecules per oocyte.
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Alternating Access Mechanism in the Lactose Permease Derived from its
Internal Symmetry
Sebastian Radestock, Lucy R. Forrest.
The lactose permease (LacY) is the prototype of themajor facilitator superfamily
(MFS) of transporters, the largest evolutionarily-related collection of secondary
transporters. The substrate transport mechanism of MFS proteins has long been
postulated to involve alternating accessibility of the substrate binding site from
either surface of themembrane. Existing structural data for LacY reveal a state in
which the substrate is exposed to the cytoplasm, but occluded from the peri-
plasm. To elucidate the conformational changes that open the permeation path-
way, we examined the internal symmetry of the LacY structure. Our analysis
revealed two sets of topologically-inverted repeats. Following ideas from our
earlier studies on LeuT and GltPh, a model of the outward-facing conformation
of LacYwas built by exchanging the conformations of the repeats. The resulting
model exhibits all required properties of an outward-facing conformation,
namely closure of the binding site residues from the cytoplasm and exposure
to the periplasm. Furthermore, the model agrees with a large amount of experi-
mental data. Analysis of differences between the two states suggests a role for
conserved sequence motifs in aiding the occlusion of the central pathway. In ad-
dition, interactions between pore-lining helicesmaybe conducted to the full con-
formational change by movements of peripheral helices. Finally, predicted re-
pairing of critical salt-bridging residues in the binding sites agree with previous
proposals. Thus, we have generated a reliable atomistic model of the outward-
facing state of LacY, using only its internal symmetry, and providing a model
for the conformational change of all MFS transporters.
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Functional Evaluation of Autism-Related Mutations in the Naþ (kþ)/ Hþ
Exchanger NHE9
Kalyan C. Kondapalli, Anniesha Hack, Maya Schushan, Nir Ben-Tal,
Rajini Rao.
A number of neurological disorders including autism, have been linked to mu-
tations in a subgroup of intracellular Naþ(Kþ)/Hþ exchangers, which include
NHE6 and NHE9 that localize to recycling and late endosomes respectively.
These are thought to mediate the electrically silent counter transport of cations
with protons. Yeast ortholog, Nhx1, has been shown to regulate endosomal pH
and control vesicular trafficking. Here, we examine the functional consequence
of missense mutations in NHE9 associated with autism, using yeast as a first
approach. Further, we extend our observations from yeast to a glial cell model,
providing the first insight into the neurobiological basis of NHE dysfunction.
Previously, a 3-dimensionalmodel of the humanNHE1was constructed using the
crystal structure of NhaA, Naþ/Hþ antiporter from Escherichia coli, as template.
